These include ALDH1, ABCG2, CD44, CD133, NANOG, and SRY-box transcription factor 2 (SOX2), all of which have been linked to chemoresistance in a number of first line anti-cancer therapies—for example, axitinib is an oral, potent, small molecule ATP-competitive multitarget tyrosine kinase inhibitor. Here, PROM1 is linked to cancer.